HC Wainwright & Co. Maintains Buy on Ocuphire Pharma, Lowers Price Target to $20
HC Wainwright & Co. analyst Matthew Caufield maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target from $26 to $20.
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers
Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast cancer cryoablation procedures.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers
NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The company's market cap stands at $2.8 million.
Ocuphire Pharma Q3 EPS $(0.22) Up From $(0.25) YoY
Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.22) per share. This is a 12 percent increase over losses of $(0.25) per share from the same period last year.
Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for…
Ocuphire Pharma Announces Last Patient Completes Final Visit In ZETA-1 Phase 2b 24-Week Trial Of Oral APX3330 In Diabetic Retinopathy
Top-line Results are Expected in 4Q 2022
Interim Masked Safety Results Seen Demonstrate Favorable Safety and Tolerability Profile, Consistent with 11 Prior Trials of APX3330
Oral APX3330 has the Potential to Serve a
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers
Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn’s Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours: